TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02268682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Guided
Description: The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Guided
Description: The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educator-Guided
Description: The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
Study: NCT03009253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: order of treatment
Description: the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: order of treatment
Description: the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
Study: NCT02069093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone based mouthwash
Description: Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
Study: NCT02910934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actellic CS
Description: Indoor residual spray with Actellic CS
Study: NCT01897519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-719
Description: Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-719
Description: Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-719
Description: Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
Study: NCT00830583

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood test
Description: There is only a blood test at the beginning.
Study: NCT04686812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worksite health promotion program
Description: Physical activity, nutrition, and stress management programs
Study: NCT02414789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Description: Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
Study: NCT00707642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN-80E
Description: Three injections of the study vaccine \[Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)\] given one month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN-80E
Description: Three injections of the study vaccine \[Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)\] given one month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN-80E
Description: Three injections of the study vaccine \[High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)\] given one month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN-80E
Description: Three injections of the study vaccine \[High Dose WN-80E API (50 µg)\] given one month apart
Study: NCT02748733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted double mini PET
Description: The modified double mini PET mimics the treatment of adapted PD and thus allows its validation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard double mini PET
Description: The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
Study: NCT04525326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX/FOLFIRI ( Standard Chemotherapy)
Description: Standard Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX/FOLFIRI ( Standard Chemotherapy)
Description: Standard Chemotherapy
Study: NCT02137226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Description: BI 695501, every two weeks for 48 weeks (25 injections in total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Humira®
Description: one injection every 2 weeks for 48 weeks (25 injections in total)
Study: NCT00041041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02791438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan granules and tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan granules and tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching azilsartan granules and tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching azilsartan granules and tablets
Study: NCT01245816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac
Description: Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine plus Placebo
Description: Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac plus Placebo
Description: Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
Study: NCT02432144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: solution for intravenous (IV) infusion
Study: NCT02062775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of self-fixating mesh for inguinal hernia repair
Description: Parietex ProGrip will be used to repair inguinal hernia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Use of non-fixating mesh for inguinal hernia repair
Description: Parietex Anatomic mesh will be used to repair inguinal hernias.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable tacks may be used in hernias >2cm
Description: Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures \>2cm
Study: NCT01124838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT02779270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987518
Description: Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen Lotion (U77-030 Control)
Description: Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
Study: NCT03092934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668
Description: Oral capsules
Study: NCT00184093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine weekly x 6 wks with concurrent external radiation
Study: NCT02455713

Intervention type: DEVICE
Intervention: PEEP and PIP
Description: Changing ventilator settings and measuring oxygen delivery and cardiac output
Study: NCT03765853

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: Usual prevention methods (ergonomic education) and Stretching Postural® postures.
Study: NCT03793374

Intervention type: OTHER
Intervention: Subcutaneous apocrine glands shaving
Description: A 0.5-cm long incision was made in the identified elliptical surgical area at each axilla for the access of arthroscopy to remove the apocrine glands. A suction-assisted cartilage shaver (E9005 System, Linvatec Corporation, Largo, Florida, USA) was introduced through the incisions to remove of the subcutaneous apocrine glands radially. After defatting, the incisions were closed primarily with 4-0 polyglactin. We anchored the defatting skin to the axillary fascia by 4-0 nylon sutures instead of the tie-over dressing or tissue glues, and we also made several drainage holes by inserting an 18G needle obliquely into the defatting skin. Therefore, draining tubes were no longer needed. We will remove the stiches at the 8th day after the operation.
Study: NCT03712267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Media Enhanced
Description: Research assistants will provide participants' therapists with information from participants' electronic messaging prior to typically scheduled clinical appointments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Research assistants will not review or provide participants' therapists with information from participants' electronic media and will compare with the Electronic Media Enhanced cohort to see if there was a difference in therapy outcomes.
Study: NCT03167255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-065/NCNP-01
Description: Received during weekly intravenous infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-065/NCNP-01
Description: Received during weekly intravenous infusions
Study: NCT00758134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin)
Description: Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
Study: NCT01473706

Intervention type: OTHER
Intervention: Consumer Mini Nutritional Assessment
Description: A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.

Intervention type: OTHER
Intervention: Consumer Mini Nutritional Assessment
Description: A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
Study: NCT03681041

Intervention type: OTHER
Intervention: Standard treatment
Description: Treatment according to guidelines for pancreatic trauma according to the Chinese Trauma Association and the American Association for the Surgery of Trauma
Study: NCT01025466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine transdermal patch (Exelon patch), memantine
Description: All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine transdermal patch
Description: All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
Study: NCT01624402

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on Stroke and Depression (ESD)
Description: * Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~* Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~* Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~* ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecosystem Focused Therapy (EFT)
Description: 1. EFT offers an action-oriented, new perspective about the subject's recovery;~2. It provides an adherence enhancement structure;~3. It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~4. It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~5. It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities.
Study: NCT03900156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: goal-setting
Description: The interviewer will have access to key information from the initial assessment such as details of identified risks. Areas where the participant would like to make changes or improvements will be identified and prioritized, and up to five specific, realistic and achievable goals will be identified.
Study: NCT01941251

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: navigated Transcranial Magnetic Stimulation
Description: * individualized α frequency~* left DLPFC 110% motor threshold (MT)~* 13-15 sessions for 3 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: navigated Transcranial Magnetic Stimulation
Description: - placebo treatment: sham coil
Study: NCT04286334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone augmentation with cad-cam laser-sintered mesh
Description: Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone augmentation with cad-cam laser-sintered mesh
Description: Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
Study: NCT00795769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Ondansetron IV
Study: NCT03919591

Intervention type: OTHER
Group type: OTHER
Intervention: Challenge virus RSV-A Memphis 37b
Description: Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
Study: NCT01216046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: capsule, taken once daily
Study: NCT04402983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
Study: NCT01216046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: tablet, taken once every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-809 placebo
Description: capsule, taken once daily
Study: NCT04005456

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Supplements and/or medical foods
Description: Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Supplements and/or medical foods
Description: Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
Study: NCT01216046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-770 placebo
Description: tablet, taken once every 12 hours
Study: NCT01485302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR228810
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR228810
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR228810
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR228810
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR228810
Description: Pharmaceutical form:solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR228810
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study: NCT02738229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02348554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled conditions
Description: The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free-living conditions
Description: The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
Study: NCT01703559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 1.0%
Description: Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 0.5%
Description: Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Description: Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
Study: NCT01245153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal Balloon Training
Description: Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Description: Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
Study: NCT01289574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-J9
Description: Cream for twice daily topical application to the face

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-J9
Description: Cream for twice daily topical application to the face

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC-J9
Description: Cream for twice daily topical application to the face